Alexander C. Flint, MD, PhD; Carol Conell, PhD; Vivek A. Rao, MD; et al.
free access
JAMA Neurol. 2014;71(11):1364-1371. doi:10.1001/jamaneurol.2014.2124
This retrospective cohort study reports that statin use is strongly associated with improved outcomes after intracerebral hemorrhage and that the cessation of statin use is strongly associated with worsened outcomes after intracerebral hemorrhage.
So-Young Huh, MD; Su-Hyun Kim, MD; Jae-Won Hyun, MD; et al.
free access
JAMA Neurol. 2014;71(11):1372-1378. doi:10.1001/jamaneurol.2014.2057
Huh et al evaluate the efficacy and safety of mycophenolate mofetil treatment in patients with neuromyelitis optica spectrum disorder. See also the Editorial by Cree.
Elizabeth C. Mormino, PhD; Rebecca A. Betensky, PhD; Trey Hedden, PhD; et al.
free access
JAMA Neurol. 2014;71(11):1379-1385. doi:10.1001/jamaneurol.2014.2031
Mormino et al determine whether neuroimaging markers of β-amyloid and neurodegeneration are independently or synergistically associated with longitudinal cognitive decline in 166 clinically normal individuals. Based on imaging markers, clinical normal individuals were categorized into preclinical Alzheimer disease stages. See the Editorial by Resnick.
Jeffrey A. Cohen, MD; Arun V. Krishnan, PhD; Andrew D. Goodman, MD; et al.
free access
JAMA Neurol. 2014;71(11):1386-1393. doi:10.1001/jamaneurol.2014.1895
Cohen et al evaluate the relationship between Timed 25-Foot Walk (T25-FW) speed and the Physical Component Summary score to understand the clinical meaning of T25-FW walking speed in multiple sclerosis.
Adam C. Naj, PhD; Gyungah Jun, PhD; Christiane Reitz, MD, PhD; et al.
free access
JAMA Neurol. 2014;71(11):1394-1404. doi:10.1001/jamaneurol.2014.1491
Naj et al investigate the effects of known AD risk loci in modifying age at onset (AAO) and estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium. Age at disease onset was abstracted from medical records among participants with late-onset AD diagnosed per standard criteria.
Ignacio F. Mata, PhD; James B. Leverenz, MD; Daniel Weintraub, MD; et al.
free access
JAMA Neurol. 2014;71(11):1405-1412. doi:10.1001/jamaneurol.2014.1455
Mata et al determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive performance in patients with Parkinson disease.
Pankaj B. Agrawal, MD; Mugdha Joshi, MBBS; Nicholas S. Marinakis, BA; et al.
free access
JAMA Neurol. 2014;71(11):1413-1420. doi:10.1001/jamaneurol.2014.1432
Agrawal et al elucidate the molecular cause of a neuromuscular disease among a family in which 4 members, a mother and her 3 sons, were affected. Two manifested nemaline myopathy, while the other 2 had a nonspecific myopathy. Whole-genome sequencing and linkage analysis identified a variant in NEFL that explains the phenotype.
Sara J. Ireland, BA; Alyssa A. Guzman, BS; Dina E. O’Brien, BS; et al.
free access
JAMA Neurol. 2014;71(11):1421-1428. doi:10.1001/jamaneurol.2014.1472
This study determined whether glatiramer acetate therapy normalizes dysregulated B-cell proliferation and cytokine production in patients with MS.